Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - OMRIX Viopharmaceuticals

Drug Profile

Immune globulin - OMRIX Viopharmaceuticals

Alternative Names: Immune deficiency immune globulin therapy - Omrix; Immunoglobulin intravenous - Omrix; Intravenous immunoglobulin - Omrix; Omr-IgG-am; Omr-IgG-am™-IVIG

Latest Information Update: 31 Jul 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autoimmune disorders; Immunodeficiency disorders

Most Recent Events

  • 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
  • 28 Sep 2006 IVIG has been licensed to FFF enterprises in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top